Average weight loss in trials: about 15% on Wegovy (semaglutide), 20% on Zepbound (tirzepatide), 8% on Saxenda (liraglutide)
A 2023 analysis of the FDA Adverse Event Reporting System (FAERS) identified increased reporting of gastroparesis among GLP-1 users compared to other diabetes medications
Dellarole IL, Vacchi E, Ruiz-Barrio I, Pinton S, Raimondi A, Rossi S, et al
Last year, Blue Cross and UMass Memorial Health narrowly avoided a contract fallout over rates, which would have forced nearly 200,000 people in Central Massachusetts to find new doctors
When one size does not fit all: reconsidering PCOS etiology, diagnosis, clinical subgroups, and subgroup-specific treatments